On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64. The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion. Operational growth was 3.9%, and adjusted operational growth was 4.0%. After good earnings results, Cantor Fitzgerald remains positive on Johnson & Johnson’s stock.  The analyst writes that numerous positive data releases and approvals for new uses of existing drugs are anticipated to boost Johnson & Johnson stock.  Cantor notes that the market is undervaluing the potential peak sales of Taris, Carvykti, Mariposa, nipocalimab, JNJ-2113, and other products.  Additionally, the pharma/medtech giant aims to ...